Initiated in 2019 and sponsored by the National Institute of Mental Health (NIMH), the Early Psychosis Intervention Network (EPINET) is a national learning health care system for early psychosis. EPINET is designed to support practice-based research to improve early identification, diagnosis, clinical assessment, intervention effectiveness, service delivery, and health outcomes in clinics offering evidence-based coordinated specialty care to persons in the early stages of psychotic illness. EPINET includes regional Hubs, first episode psychosis clinics, and the EPINET National Data Coordinating Center (ENDCC). EPINET links clinics that work with individuals with early psychosis through (1) standardized clinical measures, (2) uniform data collection methods, and (3) integration of client-level data across service users and clinics. The session will focus on the EPINET Core Assessment Battery (CAB) that was developed through a consensus process by the EPINET Steering Committee. The Steering Committee is composed of principal investigators from each of the eight regional scientific hubs and the ENDCC. The CAB includes standardized measures and individual items that assess key domains of early psychosis psychopathology, recovery, contextual factors, and treatment that can reasonably be included in the data collection efforts within first episode psychosis programs. The CAB serves as the basis for common data collection across all EPINET clinics. Data aggregated across EPINET clinics will be used to establish a national repository of early psychosis common data elements that will facilitate research to improve early psychosis identification, clinical assessment, intervention effectiveness, and recovery outcomes among individuals experiencing early psychosis. As the database grows, the national repository will be open for analyses to researchers outside of EPINET.

Format

Recorded webinar, non-interactive, self-paced distance learning activity with post-test.

This presentation was recorded on November 12, 2020 at the virtual conference, Third National Conference on Advancing Early Psychosis Care in the United States: Addressing Inequities - Race, Culture, and COVID. 

Learning Objectives

• Describe research domains important to assessment in early psychosis treatment programs.
• Explain how the EPINET Core Assessment Battery can be used by EPINET and non-EPINET clinics and researchers.
• Summarize how EPINET, as a learning health care system, can advance first episode psychosis research and clinical practice.

Outline

• Assessment in early psychosis treatment programs.
• EPINET Core Assessment Battery.
• Data and a Learning Healthcare System
• QA measures with a recovery focus.

Target Audience

Psychologists, Social Workers, and Other Mental Health Professionals

Instructional Level

Introductory

Estimate Time to Complete

Estimated Duration: 1.0 hour
Program Start Date: May 3, 2021 
Program End Date: May 3, 2024

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit™, CE credit for psychologists, CE credit for social workers, or a certificate of participation may do so by completing all sections of the course, including viewing the full video (≥60 minutes) and submitting an evaluation. A multiple-choice quiz is provided based on the content. A passing score of 75% must be achieved. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians), CE certificate (psychologists), CE certificate (social workers), or certificate of participation (other disciplines) showing the completion date and hours/credits earned.

Continuing Education Credit

Physicians

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Psychologists

The American Psychiatric Association is approved by the American Psychological Association to sponsor continuing education for psychologists. American Psychiatric Association maintains responsibility for this program and its content.

Social Workers 

American Psychiatric Association, provider #1743, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. American Psychiatric Association maintains responsibility for this course. ACE provider approval period: 05/18/2020-05/18/2021 and 05/18/2021-05/18/2024. Social workers completing this course receive 1.0 (clinical) continuing education credits.

Continuing education requirements vary from state to state. Many state boards grant reciprocity with national accrediting organizations and other state boards. It is the responsibility of each professional to understand the requirements for license renewal or check with the state or national licensing board and/or professional organization to become more familiar with their policies for acceptable continuing education credit. Social workers and Psychologists should contact their regulatory board to determine course approval.

Faculty and Planner Disclosures

Instructors

• Susan T. Azrin, Ph.D., is Unit Chief of the Early Psychosis Prediction and Prevention research unit at the National Institute of Mental Health, Division of Services and Intervention Research, where she also leads the Early Psychosis Intervention Network (EPINET) initiative. She served as Government Project Officer for the Recovery After an Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) clinical trial, a pioneering study demonstrating the effectiveness of team-based Coordinated Specialty Care for people with early psychosis. Dr. Azrin also leads the NIMH research program on improving health and reducing premature mortality in people with serious mental illness and serves as the Science Officer for the Mental Health Research Network, a learning mental health system. Reports no financial relationships with commercial interests.

• Abram Rosenblatt, Ph.D., is Vice President at Westat, where he is sector lead for Child Welfare, Justice and Behavioral Health within the Behavioral Health and Health Policy Practice. Dr. Rosenblatt is currently the Principal Investigator of the NIMH funded Early Psychosis Intervention Network Data Coordinating Center. Previously, Dr. Rosenblatt was a Professor in the Department of Psychiatry at the University of California, San Francisco. He is the author or coauthor of numerous peer-reviewed publications focusing predominantly on the costs and outcomes of multi-faceted systemic and programmatic interventions for children, youth and young adults with behavioral health needs. Reports no financial relationships with commercial interests.

• Howard H. Goldman, M.D., Ph.D., is a Professor of Psychiatry at the University of Maryland School of Medicine. He is a mental health policy researcher who has been evaluating demonstration programs for almost 40 years. Recently he has focused on demonstrations on early intervention in mental disorders to prevent disability. Dr. Goldman is the Editor Emeritus of Psychiatric Services, the journal he edited from, 2004 – 2016. He also was the Senior Scientific Editor of the Surgeon General's Report on Mental Health from 1997-1999 for which he was awarded the Surgeon General's Medallion. In 2002 he was elected to the Institute of Medicine. Reports no financial relationships with commercial interests.

• Diana Perkins, M.D., M.P.H., is a Professor and Director of OASIS (Outreach and Support Intervention Services) at the University of North Carolina School of Medicine. Dr. Perkins' research activities include psychosis risk prediction, and early intervention, as well as investigations of the genetic basis of schizophrenia. She is in the last year of the NIMH 2.9 million five-year multi-site U01 grant, 5/8-Predictors and Mechanisms of Conversion to Psychosis (NAPLS). She is co-investigator on the NIMH funded Conte Mapping Project (Ayse Belger, PI), which aims to compare the brain development trajectory using MRI and electrophysiology studies of individuals at risk of psychosis due to having an affected first degree family member compared to those with no affected relative. Dr. Perkins discloses the following relationships: Consultant: Alkermes for "Pathways Research Award" Grant/Research: Boehringer Ingelheim: UNC PI for phase 2 pharmaceutical trial.

Program Planners

• Steven Adelsheim, M.D. Reports no financial relationships with commercial interests.
• Catherine Adams, L.M.S.W., A.C.S.W., C.A.A.D.C. Reports no financial relationships with commercial interests.
• Susan T. Azrin, Ph.D.  Reports no financial relationships with commercial interests.
• Iruma Bello, Ph.D.  Reports no financial relationships with commercial interests.
• Gary Michael Blau, M.S., Ph.D.  Reports no financial relationships with commercial interests.
• Teri S. Brister, Ph.D., L.P.C.  Reports no financial relationships with commercial interests.
• Nybelle An-Vi Caruso, B.S.  Reports no financial relationships with commercial interests.
• Amy N. Cohen, Ph.D.  Reports no financial relationships with commercial interests.
• Robert O. Cotes, M.D.  Dr. Cotes discloses the following relationships: Consultant: Saladax Biomedical, American Psychiatric Association Grant/Research: Ostuka, Lundbeck, Roche, Alkermes
• Judith Dauberman, M.A., Ph.D.  Reports no financial relationships with commercial interests.
• Steven P. Dettwyler, Ph.D.  Reports no financial relationships with commercial interests.
• Lisa B. Dixon, M.D., M.P.H.  Reports no financial relationships with commercial interests.
• Melissa Edmondson Smith, Ph.D.  Reports no financial relationships with commercial interests.
• Chantel Garrett. Ms. Garrett discloses the following relationships: Stock: Invitae, stockholder Livongo, stockholder Color, private equity holder Consultant: Maine Health Northwell Health One Mind Grant/Research: One Mind National Institute of Health
• Tristan Gorrindo, M.D.  Reports no financial relationships with commercial interests.
• Kate Hardy, ClinPsych.D.  Ms. Hardy discloses the following relationships: Consultant: SME for Click Therapeutics
• Robert K. Heinssen, Ph.D., A.B.P.P. Reports no financial relationships with commercial interests.
• Brian Hepburn, M.D.  Reports no financial relationships with commercial interests.
• Patrick Kaufmann, B.S.  Reports no financial relationships with commercial interests.
• Sherin Khan, L.C.S.W. Reports no financial relationships with commercial interests.
• Steven R. Lopez, Ph.D. Reports no financial relationships with commercial interests.
• Ted Lutterman.  Reports no financial relationships with commercial interests.
• Tushita Mayanil, M.D.  Reports no financial relationships with commercial interests.
• Ryan Melton, Ph.D.  Reports no financial relationships with commercial interests.
• Oladunni Oluwoye , Ph.D.  Reports no financial relationships with commercial interests.
• Abram Rosenblatt, Ph.D.  Reports no financial relationships with commercial interests.
• David L. Shern, Ph.D.  Dr. Shern discloses the following relationships: Grant/Research: Through my employment at NASMHPD, I co-chair the dissemination function of the Early Psychosis Intervention network as part of the national data coordinating center at Westat. Westat was awarded the coordinating center grant by NIMH Other: serve on the Board of Livanta

Accessibility for Participants with Disabilities

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.

Technical Requirements

This internet-based CME activity is best experienced using any of the following:

• The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
• Internet Explorer 11+

This website requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be:  Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:

• Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
• Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
• Internet Connection: 1 Mbps or higher

Minimum Requirements:

• Windows PC: Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video content
• Macintosh: Mac OS X 10.5 or higher with latest updates installed; Intel, PowerPC G5, or PowerPC G4 (867MHz or faster) processor; 512 MB or higher RAM; audio playback with speakers for programs with video content

For assistance: Contact educme@psych.org for questions about this activity | Contact SMIadviserhelp@psych.org for technical assistance